Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Locations

United States

Start date

07/11/2025

Identifiers

Trial ID NN9536-8438,
NCT number NCT07225816,
Eudract number Not Available

Summary

The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.

Trial Overview:

Condition

Obesity

Treatment

DRUG: Liraglutide

DRUG: Oral Semaglutide

DRUG: Semaglutide

Study type

INTERVENTIONAL

Trial duration

Nov 07 2025 - Jul 17 2026

Participants

Phase

Are you eligible?

Gender

Male and female

Age

18 years and older

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

Find answers in our FAQs

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.